Roivant's Brepocitinib Beat Placebo In Both Uveitis Trials; FDA Filing Planned For First Half Of 2027
Median time to treatment failure topped 48 weeks on the pill versus about 12 weeks on placebo in each of two late-stage studies.
Roivant and its subsidiary Priovant said brepocitinib, a once-daily pill, met the main goal in both late-stage trials in non-infectious uveitis, an eye-inflammation disease, according to an 8-K filed Wednesday. Median time to treatment failure was longer than 48 weeks on the drug and about 12 weeks on placebo in each study (p<0.0001 in both).
What the results show
The press release attached to the filing says the 45 mg dose also met all key secondary goals in CLARITY-1 and CLARITY-2, the two identical studies in the program.
Pooled across both studies, 62% of brepocitinib patients reached steroid-free quiescence at Week 48, versus 20% on placebo (p<0.0001). Among patients who entered with macular edema, swelling in the retina, 42% of eyes on the drug saw it resolve, versus 4.8% on placebo (p<0.0001).
In CLARITY-1 (166 patients) the cumulative incidence of treatment failure at Week 48 was 35.4% on brepocitinib versus 78.7% on placebo. In CLARITY-2 (204 patients) it was 32.4% versus 77.8%.
The program enrolled 371 patients, randomized 1:1 to brepocitinib or placebo for 48 weeks. All patients got a mandatory steroid course that tapered to zero by Week 8. The company said the results came despite a substantially more aggressive taper than in earlier uveitis trials.
Safety, and what the company says it changes
Only 3% of participants stopped treatment because of an adverse event, the release says. Most events were mild or moderate, and the company reported no new safety signals.
Priovant intends to file a supplemental New Drug Application, a request to add this use to the drug's approval, in the first half of calendar year 2027. The drug is already sold as LISRAYA for adults with dermatomyositis.
"The breadth and magnitude of benefit seen in the CLARITY studies position brepocitinib to potentially set a new standard," said Ben Zimmer, CEO of Priovant. He called uveitis the potential next pillar of a rare disease immunology franchise.
The company estimates the disease affects 70,000 to 190,000 adults in the United States. It says the pooled benefit suggests brepocitinib has the potential to be the most effective systemic, non-steroid option, a comparison with results from trials of existing therapies.
What to watch
Roivant held an investor call at 8:00 a.m. ET Wednesday and will host an investor day on December 9, 2026. In market data, ROIV closed at $34.92 on Tuesday, up 0.63% for that session, before the release came out.
The next dated marker is the December 9, 2026 investor day, ahead of the planned filing in the first half of 2027.
Sources
- 8-K Filing — Roivant Sciences Ltd. (ROIV) — SEC EDGAR
- Exhibit ef20084121_ex99-1.htm — Roivant Sciences Ltd. 8-K exhibit — SEC EDGAR
- Roivant and Priovant Announce Positive Results in CLARITY-1 — globenewswire.com